4D Molecular Therapeutics, Inc. (FDMT)
NasdaqGS · USD · Healthcare · Biotechnology
$11.03 (+2.13%) as of
Key statistics
- Market cap
- 609.34M
- Forward P/E
- -2.69
- EPS (TTM)
- -2.63
- Dividend yield
- 0.00%
- 52-week range
- 6.96 – 16.93
- Beta
- 2.74
- Revenue (TTM)
- 92.01M
- Profit margin
- -194.74%
- Analyst target
- $28.09
- Volume
- 1.08M
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- EmeryVille, CA, United States
- Employees
- 196
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.